Through a highly collaborative research agreement with Case Western University, and through several Ethos Discovery relationships (Northwestern University, Panacea, Inc.), the most promising agents will be evaluated in cell-based, ex vivo, and then in vivo in osteosarcoma studies, with the intent of identifying the most promising agents to advance into early phase studies in dogs.
These projects will improve outcomes and alleviate suffering from bone tumors in dogs and children.
Osteosarcoma is the most common bone tumor of dogs and children. In both groups the disease is characterized by a primary bone tumor that develops within one of the long bones of the body. Despite the successful treatment of the primary bone tumor (often by amputation), the disease progresses in both groups due to metastasis. The recognition of the similarities in the biology and behavior of these cancers in dogs and children has led to opportunities for investigators in veterinary and human oncology to collaborate. There is currently a nation-wide and fully integrated human–canine clinical trial program that has received a $5 million dollar pledge from the Morris Animal Foundation, has received organizational leadership from the NIH, and has received additional support from the Quad W Foundation. To build on this opportunity, Ethos Discovery seeks to address gaps using this exciting, integrated, and comparative approach. We aim to fulfill the promise by identifying novel molecules that may be effective in preventing this cancer from metastasizing in dogs, and translate these improvements to humans. Additionally, we seek to develop a liquid biopsy approach to osteosarcoma diagnosis through the detection of circulating tumor DNA in the blood.
The gap that Ethos Discovery will fill in this collaborative and cross species approach to osteosarcoma research is a mechanism to identify promising new drugs in the laboratory setting and conduct small scale feasibility studies of these novel treatment approaches in the dog. The results of these studies will enable improved prioritization for larger scale nationwide studies (Morris Animal Foundation, NIH).
Ethos Discovery is uniquely positioned to address these gaps and deliver better treatment outcomes for both human and veterinary osteosarcoma patients. This win-win outcome for both species occurs as a result of the high similarities between the diseases. This results in a highly relevant preclinical model for human osteosarcoma and a robust drug development portfolio that targets the primary unmet therapeutic need for both patient populations.